1. YONDELIS®: Giving Patients More Time34
Case Study Name:
YONDELIS®: Giving Patients More Time
Department/BU: Medical ROI – Pharmaceutical Division
Owner: Caitriona Moylan / Barry Donovan
Date: /09/2017
CASE STUDY

2. YONDELIS®: Giving Patients More Time
The challenge
Our approach
Results
A partnership with PharmaMar which grows stronger each year with further exciting products in the pipeline.
Drug and protocol approval and registration with the HPRA, NCCP, and ODMS in Ireland.
Ambulatory patients receiving treatment and thus providing cost savings to the hospitals.
Aquilant Pharmaceuticals/PharmaMar are now seen as the lead sponsor and supporter of Soft Tissue Sarcoma in Ireland with the Irish Sarcoma Group and committee.
Increased usage and awareness year on year leading to sales growth and higher return.
Promoting a product that we are proud of and ultimately giving patients more time.
PharmaMar is an Oncology focused company committed to research and development which takes inspiration from the sea to discover molecules with antitumor activity for patient treatment.
Since the European registration of YONDELIS® in 2007, a lack of resources and support offered by a competitor company lead to very little awareness, clinical knowledge, and product growth within the Irish market.
Oncologists and patients did not have an awareness of this advanced and favourable chemotherapy treatment option available.
In 2014, Aquilant Pharmaceuticals approached PharmaMar with a specialist promotional service proposal: to use an already existing Oncology specialist team to promote and provide clinical support for Yondelis nationwide.
The team conducted advanced market research with National Oncology Governing Bodies, indentified all KOL’s within the areas of Soft Tissue Sarcoma and Ovarian Cancer, and began to work closely with the Specialist Oncology Centres to provide the deserved support for PharmaMar/YONDELIS® in Ireland.
CASE STUDY

3. FDA/EMA HPRA/NCCP Approval
YONDELIS®: Giving Patients More Time
Time
The Sea
The Laboratory
FDA/EMA HPRA/NCCP Approval
Patients
CASE STUDY